Expression of additional transcription factors is of prognostic value for aggressive behavior of pituitary adenomas

J Neurosurg. 2020 Apr 17;134(3):1139-1146. doi: 10.3171/2020.2.JNS2018.

Abstract

Objective: According to the latest WHO classification of tumors of endocrine organs in 2017, plurihormonal adenomas are subclassified by their transcription factor (TF) expression. In the group of plurihormonal adenomas with unusual immunohistochemical combinations (PAWUC), the authors identified a large fraction of adenomas expressing TFs for gonadotroph adenoma (TFGA) cells in addition to other TFs. The aim of this study was to compare clinicopathological parameters of PAWUC with TFGA expression to gonadotroph adenomas that only express TFGA.

Methods: This retrospective single-center series comprises 73 patients with TFGA-positive pituitary adenomas (SF1, GATA3, estrogen receptor α): 22 PAWUC with TFGA (TFGA-plus group) and 51 with TFGA expression only (TFGA-only group). Patient characteristics, outcome parameters, rate of invasiveness (assessed by direct endoscopic inspection), and MIB1 and MGMT status were compared between groups.

Results: Patients in the TFGA-plus group were significantly younger than patients in the TFGA-only group (age 46 vs 56 years, respectively; p = 0.007). In the TFGA-only group, pituitary adenomas were significantly larger (diameter 25 vs 18.3 mm, p = 0.002). Intraoperatively, signs of invasiveness were significantly more common in the TFGA-plus group than in the TFGA-only group (50% vs 16%, p = 0.002). Gross-total resection was significantly lower in the nonfunctioning TFGA-plus group than in the TFGA-only group (44% vs 86%, p = 0.004). MIB1 and MGMT status showed no significant difference between groups.

Conclusions: These data suggest a more aggressive behavior of TFGA-positive adenomas if an additional TF is expressed within the tumor cells. Shorter radiographic surveillance and earlier consideration for retreatment should be recommended in these adenoma types.

Keywords: WHO classification; aggressive pituitary adenoma; pituitary surgery; plurihormonal adenoma; transcription factor.

MeSH terms

  • Adenoma / classification
  • Adenoma / genetics*
  • Adenoma / pathology*
  • Adult
  • Age Factors
  • Aged
  • DNA Modification Methylases / genetics
  • DNA Repair Enzymes / genetics
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Gonadotropins / genetics
  • Humans
  • Ki-67 Antigen / genetics
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Pituitary Hormones / metabolism
  • Pituitary Neoplasms / classification
  • Pituitary Neoplasms / genetics*
  • Pituitary Neoplasms / pathology*
  • Prognosis
  • Retrospective Studies
  • Transcription Factors / genetics*
  • Treatment Outcome
  • Tumor Suppressor Proteins / genetics
  • Young Adult

Substances

  • Gonadotropins
  • Ki-67 Antigen
  • Pituitary Hormones
  • Transcription Factors
  • Tumor Suppressor Proteins
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes